Showing 4691-4700 of 5771 results for "".
- WHA 73—COVID-19, Eye Health and IAPB Statement on Behalf of the Global Eye Care Sectorhttps://modernod.com/news/wha-73-covid-19-eye-health-and-iapb-statement-on-behalf-of-the-global-eye-care-sector/2477819/The 73rd World Health Assembly (WHA) recently took place. The annual convention typically brings together health ministers, international organizations and NGOs in Geneva for a week of speeches, technical briefings, side events and meetings. However, for the first time in the WHA’s history the me
- EyeArt Accuracy Results Published in British Journal of Ophthalmologyhttps://modernod.com/news/eyeart-accuracy-results-published-in-british-journal-of-ophthalmology/2477812/Eyenuk announced that the British Journal of Ophthalmology published the
- Genentech: Longer-Term Data Reinforce Safety of Satralizumab in Adults and Adolescents With NMOSDhttps://modernod.com/news/genentech-longer-term-data-reinforce-safety-of-satralizumab-in-adults-and-adolescents-with-nmosd/2477813/Genentech will present new pooled pivotal satralizumab safety results for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disorder. These data are being presented at the 6th annual meeting of the European Academy of Neurology (EAN) and
- Aldeyra Therapeutics Advances Investigational HSP90 Inhibitor to Clinical Testing for COVID-19https://modernod.com/news/aldeyra-therapeutics-advances-ivestigational-hsp90-inhibitor-to-clinical-testing-for-covid-19/2477799/Aldeyra Therapeutics, which has several drug candidates for the treatment of ocular inflammatory diseases, announced the planned advancement of the investigational new HSP90 inhibitor ADX-1612 to clinical testing for COVID-19, and provided an update on ADX-629, a novel investigational RASP inhibi
- Clyraguard Shows Complete Inactivation of SARS-CoV-2 Virus in Study at Galveston National Labhttps://modernod.com/news/clyraguard-shows-complete-inactivation-of-sars-cov-2-virus-in-study-at-galveston-national-lab/2477802/Clyra Medical Technologies announced that it has received test results showing that its proprietary copper iodine antimicrobial and antiviral product, Clyraguard, successfully inactivated the COVID-19 coronavirus (SARS-CoV-2 virus). Testing was conducted by the laboratory of Slobodan Paess
- TearClear Appoints Dr. Amir Shojaei Chief Development Officerhttps://modernod.com/news/tearclear-appoints-dr-amir-shojaei-chief-development-officer/2477803/TearClear Corp. announced the appointment of Amir Shojaei, PharmD, PhD, as Chief Development Officer. Over his 23-year career, Dr. Shojaei has focus
- Roche Antibody Test for COVID-19 Goes Live at More Than 20 Initial Lab Sites in the UShttps://modernod.com/news/roche-antibody-test-for-covid-19-goes-live-at-more-than-20-initial-lab-sites-in-the-us/2477797/Roche announced its Elecsys Anti-SARS-CoV-2 antibody test is live at more than 20 commercial and hospital lab sites throughout the United States, with plans in the next several weeks to increase to more than 200 commercial and hospital lab sites with the ability t
- Atia Vision Closes Second Tranche Of $20M In Series D Financinghttps://modernod.com/news/atia-vision-closes-second-tranche-of-20m-in-series-d-financing/2477793/Atia Vision, which is developing of a modular presbyopia-correcting accommodating IOL, announced the closing of its second tranche of a Series D $20M financing. The financing will be used to continue early clinical experience treating cataract patients and support ex
- Kubota Vision Introduces Electronic Eyeglasses to Stop Myopia in Childrenhttps://modernod.com/news/kubota-vision-introduces-electronic-eyeglasses-to-stop-myopia-in-children/2477794/Kubota Vision announced positive clinical results from myopia control tests in humans. Utilizing electronic tabletop optical projection devices that embody Kubota Glasses technology, myopically-defocused images were projected on the peripheral retina of subjects to study if progression of myopia
- BVI Expands Portfolio with New Viscoelastic; Forges Strategic Partnership with Cromahttps://modernod.com/news/bvi-expands-portfolio-with-new-viscoelastic-forges-strategic-partnership-with-croma/2477789/BVI announced it has acquired the ophthalmic viscoelastic device (OVD) assets from Austrian-based Croma. In addition to the acquisition of existing products, BVI and Croma have embarked on an R&D collaboration on additional products that will come to market. Terms of the deal were not